The 7-OH 1 mg per Gram 100 to 1 Ratio: What the October 2026 Kratom Notice Means for Mitragynine (MIT) Tablets

On October 9, 2026, the Department of Justice (DOJ) said the DEA will issue a new notice proposing Schedule I control of 7-OH and MGPI only above set limits. The 7-OH 1 mg per gram 100 to 1 ratio proposal covers products with more than 1 mg per gram or mL, or too little mitragynine relative to 7-OH.

Nothing is final yet. The Department of Health and Human Services (HHS) recommended the limits, and DEA says it will adopt them in a new Notice of Intent. Three related compounds are already controlled, as covered in our post on the DEA's August 2026 order for MGPI, MGM-15 and MGM-16.

Status as of October 12, 2026: The thresholds are proposed (DOJ release 26-1165). The new 7-OH notice is not yet in the Federal Register, and no 7-OH temporary order exists. Mitragynine and kratom leaf are not federally scheduled. MGPI, MGM-15 and MGM-16 remain Schedule I. State laws vary.

What did DOJ announce on October 9, 2026?

DOJ said DEA will issue two new Notices of Intent based on new HHS recommendations. The first, for 7-OH and MGPI, adds a concentration limit and a mitragynine ratio test. The second reissues the MGM-15 and MGM-16 notice without changing the scheduling approach. DOJ confirmed that no temporary order for 7-OH had been issued.

The Schedule I controls placed on MGPI, MGM-15 and MGM-16 on August 26, 2026, stay in force until DEA issues a new temporary order.

What is the 7-OH 1 mg per gram 100 to 1 ratio proposal?

It is a two-part test. Under the HHS recommendation, 7-OH and MGPI would fall under temporary Schedule I control in a product that meets either condition: more than 1 mg of 7-OH, MGPI or both combined per gram of a solid or per milliliter of a liquid, or a mitragynine ratio below 100 to 1.

Meeting one condition is enough. HHS says the per-gram figure covers solid, powder and encapsulated forms, and liquids are measured per milliliter.

What does the 100:1 mitragynine ratio mean?

HHS defines the ratio as the mass of mitragynine divided by the mass of 7-OH, MGPI or both combined. If the result is less than 100, the ratio test is met. Put simply, a product with fewer than 100 parts mitragynine for every part 7-OH and MGPI, by mass, would fall within the proposal.

Mitragynine sits at the center because HHS describes it as the predominant alkaloid in kratom, while 7-OH occurs naturally only at low or trace levels. Our guide to kratom alkaloids covers how these compounds relate.

HHS says the ratio reflects the alkaloid makeup of natural kratom. DEA's July notice gave similar context, describing 7-OH as less than two percent of the plant's total alkaloid content.

How does the new proposal compare with the July 2026 notice?

The July 6, 2026 notice (91 FR 40917, Docket DEA-1570) set a percentage threshold for 7-OH alone. The October proposal, as DOJ and HHS describe it, uses a per-gram or per-milliliter limit, adds a mitragynine ratio test and applies the same threshold approach to MGPI.

Feature	July 6, 2026 notice	October 9, 2026 announcement
Compounds	7-OH	7-OH and MGPI, alone or combined
Concentration test	More than 0.050% 7-OH (dry weight for plant material), or more than 1.00 mg in a processed or synthetic article	More than 1 mg per gram (solids) or 1 mg per mL (liquids)
Ratio test	None	Mitragynine to 7-OH and MGPI below 100 to 1
MGPI	Separate notice; Schedule I in any amount since August 26, 2026	Threshold approach proposed; current control stays until a new order issues
Status on October 12, 2026	Notice published; no order issued	Announced; new notice not yet found in the Federal Register

Does the threshold ban kratom leaf?

Not on its face. Kratom leaf and mitragynine are not federally scheduled, and HHS says the thresholds aim to separate concentrated or chemically altered products from natural botanical kratom. Neither release expressly excludes leaf, though, so how any leaf product is treated depends on the final text and its measured content.

HHS Secretary Robert F. Kennedy, Jr. described the approach as drawing a clear line between natural kratom and enhanced opioid products.

Federal rules are only part of the picture. Several states ban kratom outright, and others restrict concentrated 7-OH while leaving leaf legal.

Does the notice cover MIT extracts and tablets?

The notice is relevant to MIT products because mitragynine is the reference point of the ratio test. It does not propose scheduling mitragynine. Whether a given mitragynine product would be covered depends on its measured 7-OH and MGPI content, how the final notice defines measurement, and state law.

7Stax makes Nano Tech Mitragynine tablets, so we are following this notice closely. We cannot say how the final text will apply to any specific product, including our own, and nothing here is a product compliance assessment.

For background on the format itself, see what MIT tablets are and our comparison of nano tech and traditional kratom tablets. Products in this category are intended only for adults 21 and over.

What happens next, and when?

DEA must first publish the new Notice of Intent in the Federal Register. Under 21 U.S.C. 811(h), a temporary order cannot issue until 30 days after that notice. If issued, an order takes effect on publication, lasts two years and can be extended by up to one year while permanent scheduling proceeds.

1. DEA publishes the new Notice of Intent. No date has been announced.
2. The 30-day period runs. By statute, DEA must consider any comments HHS submits.
3. DEA may then issue a temporary scheduling order, effective when published.
4. The order lasts two years. Permanent control would require separate scheduling proceedings.

What is still unknown?

Several details will only be clear once the new notice is published: its exact wording and date, how labs are expected to measure the ratio, and whether the per-article milligram measure from July carries over. No effective date has been announced, and neither release sets one.

• Final definitions, including whether July's botanical and processed categories remain.
• Testing methods for both tests. Neither release names one.
• How states respond to the federal thresholds.

Frequently Asked Questions

Is mitragynine a controlled substance?

Not federally. Mitragynine is not listed in the federal schedules, and neither the July notice nor the October announcement proposes scheduling it. It serves as the reference compound in the ratio test. Some states ban or restrict kratom and its alkaloids, so state law still applies.

Does the 100 to 1 ratio also apply to MGPI?

Yes, as proposed. HHS measures mitragynine against 7-OH, MGPI or their combined mass. HHS said the science on MGPI is still developing but recommended the same approach for both compounds.

Can the public comment on the new notice?

Neither release describes a new comment window. In the earlier round, HHS ran a request for information under docket HHS-OASH-2026-0232, which closed on September 10, 2026. The July DEA notice itself did not invite public comments.